CSL Behring is a global leader in the plasma protein biotherapies industry, dedicated to treating rare and serious diseases and passionate about improving the quality of life of patients throughout the world.
We trace our corporate roots back to Emil von Behring, an innovator with serum therapies who won the first Nobel Prize in Physiology and Medicine. Innovation remains a core value of the company today. The company recently changed its name from ZLB Behring as part of our alignment with our parent organisation, CSLTM, a specialty biopharmaceutical company with heritage of contributions to human health for more than 90 years.
CSL Behring's comprehensive line of therapies includes:
â€¢Plasma-derived and recombinant coagulation factors for the treatment of haemophilia, von Willebrand disease and other bleeding disorders – less–ZoomInfo